Tags

Type your tag names separated by a space and hit enter

Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Drugs. 1991; 42 Suppl 3:34-40.D

Abstract

Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. In the gastrointestinal tract, cefpodoxime proxetil is hydrolysed to cefpodoxime, which has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections: Haemophilus influenzae, Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains), and Streptococcus pneumoniae (including amoxicillin-resistant strains). Six randomised comparative studies in patients with lower respiratory tract infections, 5 of which were large (enrollment of more than 200 patients) and double-blind, examined the efficacy and safety of cefpodoxime proxetil. Cefpodoxime proxetil (at a dosage equivalent to 200mg of cefpodoxime) administered twice daily for 5 to 10 days was similar in clinical and bacteriological efficacy to the following: amoxicillin 500mg 3 times daily in the treatment of community-acquired pneumonia; intramuscular ceftriaxone Ig once daily in the treatment of pulmonary infections in hospitalised patients; and to amoxicillin/clavulanic acid 500/125mg 3 times daily in the treatment of acute exacerbations of chronic bronchitis (AECB). Additionally, a dosage equivalent to 100mg or 200mg of cefpodoxime twice daily was similar in clinical and bacteriological efficacy to amoxicillin 250mg 3 times daily in the treatment of bronchitis (acute or AECB). The adverse events noted with cefpodoxime proxetil administration were similar to those associated with other beta-lactam antibacterials and most commonly involved the gastrointestinal tract and skin or mucous membranes. Thus, cefpodoxime proxetil is a useful addition to the antibacterials available for the treatment of infections of the lower respiratory tract.

Authors+Show Affiliations

Department of Communicable and Tropical Diseases, East Birmingham Hospital, England.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Review

Language

eng

PubMed ID

1726206

Citation

Geddes, A M.. "Cefpodoxime Proxetil in the Treatment of Lower Respiratory Tract Infections." Drugs, vol. 42 Suppl 3, 1991, pp. 34-40.
Geddes AM. Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Drugs. 1991;42 Suppl 3:34-40.
Geddes, A. M. (1991). Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Drugs, 42 Suppl 3, 34-40.
Geddes AM. Cefpodoxime Proxetil in the Treatment of Lower Respiratory Tract Infections. Drugs. 1991;42 Suppl 3:34-40. PubMed PMID: 1726206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cefpodoxime proxetil in the treatment of lower respiratory tract infections. A1 - Geddes,A M, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 34 EP - 40 JF - Drugs JO - Drugs VL - 42 Suppl 3 N2 - Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. In the gastrointestinal tract, cefpodoxime proxetil is hydrolysed to cefpodoxime, which has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections: Haemophilus influenzae, Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains), and Streptococcus pneumoniae (including amoxicillin-resistant strains). Six randomised comparative studies in patients with lower respiratory tract infections, 5 of which were large (enrollment of more than 200 patients) and double-blind, examined the efficacy and safety of cefpodoxime proxetil. Cefpodoxime proxetil (at a dosage equivalent to 200mg of cefpodoxime) administered twice daily for 5 to 10 days was similar in clinical and bacteriological efficacy to the following: amoxicillin 500mg 3 times daily in the treatment of community-acquired pneumonia; intramuscular ceftriaxone Ig once daily in the treatment of pulmonary infections in hospitalised patients; and to amoxicillin/clavulanic acid 500/125mg 3 times daily in the treatment of acute exacerbations of chronic bronchitis (AECB). Additionally, a dosage equivalent to 100mg or 200mg of cefpodoxime twice daily was similar in clinical and bacteriological efficacy to amoxicillin 250mg 3 times daily in the treatment of bronchitis (acute or AECB). The adverse events noted with cefpodoxime proxetil administration were similar to those associated with other beta-lactam antibacterials and most commonly involved the gastrointestinal tract and skin or mucous membranes. Thus, cefpodoxime proxetil is a useful addition to the antibacterials available for the treatment of infections of the lower respiratory tract. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/1726206/Cefpodoxime_proxetil_in_the_treatment_of_lower_respiratory_tract_infections_ L2 - https://dx.doi.org/10.2165/00003495-199100423-00008 DB - PRIME DP - Unbound Medicine ER -